Recent Updates
Recently added Catalysts

Itraconazole

Phase 3

HIV Infections | Small molecule | Infectious Disease |Johnson & Johnson|Last Updated: Jun 24, 2005

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Clinical trial landscape

Itraconazole · 1 trial · 3 indications

Phase 3 1
NCT00002159A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or HistoplasmosisHIV Infections
COMPLETED60 Analytics
PHASE3COMPLETED
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
HIV InfectionsUnlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
ItraconazoleDRUG -
Amphotericin BDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range13 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria Patients must have: * HIV positive or negative status. * Blastomycosis or histoplasmosis. * Life expectancy of at least 1 week. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Liver disease. * Self-limiting fungal ...

Countries:United States
Unlock Eligibility Criteria